Homocysteine or renal impairment which is the real cardiovascular risk factor?

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 28, Issue 6, 2008, Pages 1158-1164

  Potter, Kathleen ^a,b   Hankey, Graeme J ^a,b   Green, Daniel J ^c,d   Eikelboom, John W ^e   Arnolda, Leonard F ^a,b  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b ROYAL PERTH HOSPITAL   (Australia)

^c LIVERPOOL JOHN MOORES UNIVERSITY   (United Kingdom)

^d UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^e MCMASTER UNIVERSITY   (Canada)

Author keywords

Carotid intima medial thickness; Cystatin c; Flow mediated dilation; Homocysteine; Stroke

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; CREATININE; CYANOCOBALAMIN; CYSTATIN C; DIPYRIDAMOLE; DIURETIC AGENT; FOLIC ACID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO; PYRIDOXINE; WARFARIN; BIOLOGICAL MARKER; CYSTATIN;

AGED; AMINO ACID BLOOD LEVEL; ARTERIAL WALL THICKNESS; ARTERY DILATATION; ARTICLE; BRACHIAL ARTERY; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FOLIC ACID BLOOD LEVEL; GLOMERULUS FILTRATION RATE; GROUPS BY AGE; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; SMOKING; STROKE; SYSTOLIC BLOOD PRESSURE; TABLET; VITAMIN BLOOD LEVEL; VITAMIN SUPPLEMENTATION; BLOOD; BLOOD FLOW; CARDIOVASCULAR DISEASE; CAROTID ARTERY; FOLLOW UP; KIDNEY DISEASE; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PREDICTION AND FORECASTING; REGRESSION ANALYSIS; RISK FACTOR;

AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; BRACHIAL ARTERY; CARDIOVASCULAR DISEASES; CAROTID ARTERIES; CROSS-SECTIONAL STUDIES; CYSTATINS; FEMALE; FOLIC ACID; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HOMOCYSTEINE; HUMANS; KIDNEY DISEASES; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; REGIONAL BLOOD FLOW; REGRESSION ANALYSIS; RISK FACTORS; VITAMIN B 12; VITAMIN B 6;

EID: 44849114993     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/ATVBAHA.108.162743     Document Type: Article

References (33)

1. Arnadottir M, Hultberg B, Nilsson-Ehle P, Thysell H. 'Oie effect of reduced glomerular filtration rate on plasma total homocysteine concentration. Scand J Clin Lab Invest. 1996;56:41-46.
2. Wrone EM, Hornberger JM, Zehnder JL, McCann LM, Coplón NS, Fortmann SP. Randomized trial of folic acid for prevention of cardiovascular events in end-stage renal disease. J Am Soc Nephrol. 2004; 15: 420-426.
3. Jamison RL, Hartigan P, Kaufman JS, Goldfarb DS, Warren SR, Guarino PD, Gaziano JM, For the Veterans Affairs Site Investigators. Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal, disease: a randomized controlled trial. JAMA. 2007;298:1163-1170.
4. Mann JFE, Sheridan P, McQueen MJ, Held C, Arnold JMO, Fodor G, Yusuf S, Lonn EM, on behalf of the HOPE-2 investigators. Homocysteine lowering with folic acid and. B vitamins in people with chronic kidney disease results of the renal Hope-2 study. Nephrol Dial Transplant. 2007:gfm485.
5. Shlipak MG, Katz R, Sarnak MJ, Fried LF, Newman AB, Stehman-Breen C, Seliger SL, Kestenbaum B, Psaty B, Tracy RP, Siscovick DS. Cystatin C and prognosis for cardiovascular and kidney outcomes in elderly persons without chronic kidney disease. Ann Intern Med. 2006;145: 237-246.
6. Van Biesen W, De Bacquer D, Verbeke F, Delanghe J, Lameire N, Vanholder R. The glomerular filtration rate in an apparently healthy population and its relation with cardiovascular mortality during 10 years. Eur Heart J. 2007;28:478-483.
7. Bostom AG, Bausserman L, Jacques PF, Liaugaudas G, Selhub J, Rosenberg IH. Cystatin C as a determinant of fasting plasma total homocysteine levels in coronary artery disease patients with normal serum creatinine. Arterioscler Thromb Vase Biol. 1999;19:2241-2244.
8. Stehouwer CD, Weijenberg MP, van den Berg M, Jakobs C, Feskens EJ, Kromhout D. Serum homocysteine and risk of coronary heart disease and cerebrovascular disease in elderly men: a 10-year follow-up. Arterioscler Thromb Vase Biol, 1998;18:1895-1901.
9. Adachi H, Hirai Y, Fujiura Y, Matsuoka H, Satoh A, Imaizumi T. Plasma homocysteine levels and atherosclerosis in Japan: epidemiological study by use of carotid ultrasonography. Stroke. 2002;33:2177-2181.
10. Roos JF, Doust J, T'ett SE, Kirkpatrick CMJ. Diagnostic accuracy of cystatin C compared to serum creatinine for die estimation of renal dysfunction in adults and children-A meta-analysis. Clin Biochem. 2007; 40:383-391.
11. The VITATOPS Trial Study Group. The VITATOPS (Vitamins to Prevent Stroke) trial: rationale and design of an International, large, simple, randomised trial of homocysteine-lowering multivitamin therapy in patients with recent transient ischaemic attack or stroke. Cerebrovas Dis. 2002;13:120-126.
12. Potter K, Green DJ, Reed CJ, Woodman RF, Watts GF, McQuillan BM, Burke V, Hankey GJ, Amolda LF. Carotid intima-medial thickness measured, on multiple ultrasound frames: evaluation of a DICOM-based software system. Cardiovasc Ultrasound. 2007;5:29.
13. Woodman RJ, Playford DA, Watts GF, Cheetham C, Reed C, Taylor RR, Puddey IB, Beilin LJ, Burke V, Mori TA, Green D. Improved analysis of brachial artery ultrasound using a novel edge-detection software system. J Appl Physiol. 2001;91:929-937.
14. Chronic Kidney Disease Epidemiology Collaboration. Using standardized serum, creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med. 2006;145:247-254.
15. Andel J. On non-nested regression models. Comment Math Univ Carolinae. 1993;34:335-340.
16. Woo KS, Chook P, Lolin YI, Cheung AS, Chan LT, Sun YY, Sanderson JE, Metreweli C, Celermajer DS. Hyperhomocyst(e)inein:ia is a risk factor for arterial endothelial dysfunction in humans. Circulation. 1997;96: 2542-2544.
17. Tawakol A, Omland T, Gerhard M, Wu JT, Creager MA. Hyperhomocyst(e)inemia is associated with impaired endothelium-dependent vasodilation in humans. Circulation. 1997;95:1119-1121.
18. Hirsch S, de la Maza P, Mendoza L, Petermann M, Glasinovic A, Paulinelli P, Barrera G, Rosenberg IH, Bunout D. Endodielial function in healthy younger and older hyperhomocysteinemic subjects. J Am Geriatr Soc. 2002;50:1019-1023.
19. Hanratty CG, McAuley DF, McGrath LT, Young IS, Johnston GD. Hyperhomocysteinaemia in young adults is not associated with impaired endodielial function. Clin Sci (Land). 2001;100:67-72.
20. Woodman RJ, Celermajer DE, Thompson PL, Hung J. Folic acid does not improve endothelial function in healthy hyperhomocysteinaemic subjects. Clin Sci. (Land). 2004;106:353-358.
21. Hirsch S, Ronco AM, Vasquez M, de la Maza MP, Garrido A, Barrera G, Cartas V, Glasinovic A, Leiva L, Bunout D. Hyperhomocysteinemia in healthy young men and elderly mm with normal serum folate concentration is not associated with poor vascular reactivity or oxidative stress. J Nutr. 2004;134:1832-1835.
22. J'uonala M, Viikari JSA, Alfthan G, Marniemi J, Kahonen M, Taittonen L, Laitinen T, Raitakari OT. Brachial artery flow-mediated dilation and asymmetrical dimethylarginine in the Cardiovascular Risk in Young Finns study. Circulation. 2007;116:1367-1373.
23. Malinow MR, Nieto FJ, Szklo M, Chambless LE, Bond G. Carotid artery intimal-medial wall thickening and plasma homocyst(e)ine in asymptomatic adults. The Atherosclerosis Risk in Communities Study. Circulation. 1993;87:1107-1113.
24. Bots ML, Launer LJ, Lindemans J, Hofman A, Grobbee DE. Homocysteine, atherosclerosis and prevalent cardiovascular disease in the elderly: The Rotterdam Study. J Intern Med. 1997;242:339-347.
25. Tsai MY, Arnett DK, Eckfeldt JH, Williams RR, Ellison RC. Plasma homocysteine and its association with carotid intimal-medial wall thickness and prevalent coronary heart disease: NHLBI Family Heart Study. Atherosclerosis. 2000;151:519 524.
26. Linnebank M, Moskau S, Farmand S, Fliessbach K, Kolsch H, Bos M, Grothe C, Becker D, Harbrecht U, Pohl C, Wuilner U, Klockgether T. Homocysteine and carotid intima-media thickness in a German population. Lack of clinical relevance. Stroke. 2006;37:2840-2842.
27. Mazza A, Motti C, Nulli A, Marra G, Gnasso A, Pastore A, Federici G, Córlese C. Lack of association between carotid intima-media thickness and methylenetetrahydrofolate reductase gene polymorphism or serum homocysteine in non insulin-dependent diabetes mellitus. Metabolism. 2000;49:718-723.
28. Durga J, Verhoef P, Bots ML, Schoulen E. Homocysteine and carotid intima-media thickness: a critical appraisal of the evidence. Atherosclerosis. 2004;176:1-19.
29. Watanabe S, Okura T, Liu J, Miyoshi K-i, Fukuoka T, Hiwada K, Higaki J. Serum cystatin C level is a marker of end-organ damage in patients with essential hypertension. Hypertens Res. 2003;26:895-899.
30. Rodondi N, Yerly P, Gabriel. A, Riesen WF, Bumier M, Paccaud F, Bovet P. Microalbuminuria, but not cystatin C, is associated, witii carotid, atherosclerosis in middle-aged adults. Nephrol Dial Transplant. 2007;22:1107-1114.
31. Durga J, Bots ML, Schouten EG, Kok FJ, Verhoef P. Low concentrations of folate, not hyperhomocysteinemia, are associated witii carotid intima-media diickness. Atherosclerosis. 2005;179:285-292.
32. Brown KS, Huang Y, Lu Z-Y, Jian W, Blair IA, Whitehead AS. Mild folate deficiency induces a proatherosclerotic phenotype in endodielial cells. Atherosclerosis. 2006;189:133-141.
33. Wang J, Sim AS, Wang XL, Saionikas C, Moriatis M, Naidoo D, Wilcken DE. Relations between markers of renal function, coronary risk factors and. the occurrence and severity of coronary artery disease. Atherosclerosis. In press.